Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.

Abstract

Gallium-68 fibroblast activation protein inhibitor [(⁶⁸Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(¹⁸F)FDG] using positron emission tomography (PET). While imaging oncology patients with [⁶⁸Ga]Ga-FAPI PET, incidental uptake of [⁶⁸Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.